NPI: 1245430446 · HENDERSON, NV 89014 · 261QE0700X
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 12,144 | $150K |
| 2019 | 21,535 | $238K |
| 2020 | 16,374 | $251K |
| 2021 | 11,127 | $329K |
| 2022 | 15,268 | $405K |
| 2023 | 5,657 | $392K |
| 2024 | 2,580 | $399K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | 39,565 | 1,560 | $2.16M | |
| Q4081 | Epoetin alfa, 100 units esrd | 29,647 | 935 | $4K |
| 82728 | 403 | 176 | $24.14 | |
| 85041 | 1,045 | 480 | $2.67 | |
| 85048 | 961 | 454 | $2.28 | |
| A4657 | Syringe w/wo needle | 2,471 | 723 | $0.00 |
| J1270 | Injection, doxercalciferol | 5,289 | 231 | $0.00 |
| 83550 | 411 | 178 | $0.00 | |
| 82306 | 215 | 95 | $0.00 | |
| 82746 | 61 | 27 | $0.00 | |
| 82607 | 35 | 14 | $0.00 | |
| G0499 | Hepb screen high risk indiv | 86 | 16 | $0.00 |
| J1756 | Iron sucrose injection | 3,558 | 480 | $0.00 |
| 83540 | 435 | 190 | $0.00 | |
| 83970 | 477 | 199 | $0.00 | |
| J0887 | Epoetin beta esrd use | 26 | 12 | $0.00 |